The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...
The Biden administration is proposing a new rule to significantly expand the coverage of weight-loss drugs for Americans on ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
The Biden administration is proposing a rule that would require the US government to cover obesity drugs for millions of ...
5h
Millions of obese Americans would be eligible to have drugs like Wegovy or Zepbound covered by Medicare or Medicaid under the ...
The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...
The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.
Eli Lilly gained 4.5%, while Danish Ozempic maker Novo Nordisk rose 1.8%. Novo Nordisk Chief Financial Officer Karsten Knudsen noted that it was unclear whether the Trump administration would confirm ...
Despite Eli Lilly's underperformance in GLP-1 sales, Novo Nordisk's diabetes and obesity treatments, especially Ozempic and Wegovy, continue to show robust growth. Legal concerns over compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback